Literature DB >> 7755681

Parkinson's disease.

C D Marsden1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7755681      PMCID： PMC1072968          DOI： 10.1136/jnnp.57.6.672

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  104 in total

Review 1.  Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease.

Authors:  J T Hutton; J L Morris
Journal:  Neurology       Date:  1992-01       Impact factor: 9.910

2.  Off-period screaming accompanying motor fluctuations in Parkinson's disease.

Authors:  M J Steiger; N P Quinn; B Toone; C D Marsden
Journal:  Mov Disord       Date:  1991       Impact factor: 10.338

Review 3.  On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics.

Authors:  J G Nutt
Journal:  Ann Neurol       Date:  1987-10       Impact factor: 10.422

4.  Protein redistribution diet restores motor function in patients with dopa-resistant "off" periods.

Authors:  J H Pincus; K Barry
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

5.  Antemortem diagnosis of diffuse Lewy body disease.

Authors:  H A Crystal; D W Dickson; J E Lizardi; P Davies; L I Wolfson
Journal:  Neurology       Date:  1990-10       Impact factor: 9.910

6.  Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus.

Authors:  A L Benabid; P Pollak; C Gervason; D Hoffmann; D M Gao; M Hommel; J E Perret; J de Rougemont
Journal:  Lancet       Date:  1991-02-16       Impact factor: 79.321

7.  Motor blocks in Parkinson's disease.

Authors:  N Giladi; D McMahon; S Przedborski; E Flaster; S Guillory; V Kostic; S Fahn
Journal:  Neurology       Date:  1992-02       Impact factor: 9.910

8.  Increase of Parkinson disability after fluoxetine medication.

Authors:  E N Steur
Journal:  Neurology       Date:  1993-01       Impact factor: 9.910

9.  Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.

Authors:  L I Golbe; A N Lieberman; M D Muenter; J E Ahlskog; G Gopinathan; A N Neophytides; S H Foo; R C Duvoisin
Journal:  Clin Neuropharmacol       Date:  1988-02       Impact factor: 1.592

10.  Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease.

Authors:  V Kostic; S Przedborski; E Flaster; N Sternic
Journal:  Neurology       Date:  1991-02       Impact factor: 9.910
View more
  49 in total

1.  Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats.

Authors:  W Y Lee; J W Chang; N L Nemeth; U J Kang
Journal:  J Neurosci       Date:  1999-04-15       Impact factor: 6.167

Review 2.  Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

Authors:  Teus van Laar
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

3.  Efficient production of mesencephalic dopamine neurons by Lmx1a expression in embryonic stem cells.

Authors:  Stina Friling; Elisabet Andersson; Lachlan H Thompson; Marie E Jönsson; Josephine B Hebsgaard; Evanthia Nanou; Zhanna Alekseenko; Ulrika Marklund; Susanna Kjellander; Nikolaos Volakakis; Outi Hovatta; Abdeljabbar El Manira; Anders Björklund; Thomas Perlmann; Johan Ericson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-21       Impact factor: 11.205

4.  Usefulness of pallidotomy in advanced Parkinson's disease.

Authors:  F Johansson; J Malm; E Nordh; M Hariz
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

5.  Risperidone in Parkinson's disease.

Authors:  A R Tavares
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-04       Impact factor: 10.154

Review 6.  Preclinical (1)H-MRS neurochemical profiling in neurological and psychiatric disorders.

Authors:  Moonnoh R Lee; Aleksandar Denic; David J Hinton; Prasanna K Mishra; Doo-Sup Choi; Istvan Pirko; Moses Rodriguez; Slobodan I Macura
Journal:  Bioanalysis       Date:  2012-07       Impact factor: 2.681

Review 7.  A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists.

Authors:  Annalisa Pinna; Micaela Morelli
Journal:  Neurotox Res       Date:  2013-12-10       Impact factor: 3.911

8.  Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.

Authors:  Eliseu Felippe dos Santos; Estela Natacha Brandt Busanello; Anelise Miglioranza; Angela Zanatta; Alethea Gatto Barchak; Carmen Regla Vargas; Jonas Saute; Charles Rosa; Maria Júlia Carrion; Daiane Camargo; André Dalbem; Jaderson Costa da Costa; Sandro René Pinto de Sousa Miguel; Carlos Roberto de Mello Rieder; Moacir Wajner
Journal:  Metab Brain Dis       Date:  2009-03-18       Impact factor: 3.584

9.  Short- and long-term dopaminergic effects on dysarthria in early Parkinson's disease.

Authors:  Sabine Skodda; Wenke Visser; Uwe Schlegel
Journal:  J Neural Transm (Vienna)       Date:  2009-12-12       Impact factor: 3.575

10.  Lateral stepping for postural correction in Parkinson's disease.

Authors:  Laurie A King; Fay B Horak
Journal:  Arch Phys Med Rehabil       Date:  2008-03       Impact factor: 3.966
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.